Pfizer, which has a major research and development operation in Connecticut, saw net income of $4.9 billion, or 60 cents a share in the first three months of the year. That’s up 33% from the same period in 2009, and beat Wall Street’s expectations.
Pfizer closed its $67 billion acquisition of Wyeth last October, and the effects were clear in this quarter’s numbers – the addition of sales of Wyeth’s most successful medicines boosted Pfizer’s revenues by more than 50%. Pfizer reaffirmed its forecasts for full year earnings, and said it doesn’t see a negative impact from the recent healthcare reform legislation.
For WNPR, I'm Harriet Jones.